最新ニュース NeueHealth (NYSE:NEUE) 株価情報

NeueHealth

NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.

NeueHealth Inc

Economist Craig Shapiro shared his insights on the unfolding U.S.-China trade dynamics, warning that while a tariff truce may calm immediate market fears, it could have unintended consequences for the broader economy.
What Happened: Shapiro, a macro strategist at Bear Traps Report, suggested that the so-called &#8220;tariff climb down&#8221; might prevent bond yields from falling, thereby maintaining pressure on an already strained economy as the Federal Reserve remains on the sidelines.
Shapiro's analysis, posted on X, builds on his earlier reflections from May 9, where he drew parallels to the 2018 Donald Trump, Xi Jinping G20 summit in Argentina. Back then, a temporary trade truce sparked market euphoria, driving a brief rally as volatility subsided.
However, the optimism was short-lived. Markets tanked in the following weeks as the reality of implementing a deal set in, compounded by a slowing economy and a Federal Reserve that was tightening policy through quantitative tightening.
The situation only stabilized after the former Treasury Secretary Steven Mnuchin's emergency Christmas Eve call to major banks and Fed Chair Jerome Powell's subsequent policy pivot in early 2019.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Sticking with this call Tariff Climb down will alleviate the worst fears but the reality is that the cave will make it hard for yields to fall which keeps the economy under pressure as the Fed sits on its hands. <a href="https://t.co/BdWKBOUf8o">https://t.co/BdWKBOUf8o</a>
&mdash; Craig Shapiro (@ces921) <a href="https://twitter.com/ces921/status/1921845051589640249?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
His comments come amid a backdrop of heightened trade tensions, with recent reports indicating that President Trump paused reciprocal tariffs for 90 days, leaving a baseline 10% rate in place. Despite this reprieve, bond yields have remained stubbornly high.
The 10-year Treasury yields jumped to 4.45% as of the publication of this article.
Thus, according to Shapiro, inflationary effects could continue to push up prices and inflation expectations, and this will prevent bond yields from falling, as investors demand higher yields to offset inflation risk and perceived economic uncertainty.
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45341850/economists-warn-of-empty-shelves-if-goods-stop-coming-from-china-amid-falling-inventory-to-sales-ratio-and-potential-tariffs">Economists Warn Of &#8216;Empty Shelves&#8217; If Goods Stop Coming From China Amid Falling Inventory-To-Sales Ratio And Potential Tariffs</a>
Why It Matters: On Monday, the U.S. and China declared a <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">90-day suspension</a> of reciprocal tariffs, reducing them from 125% to 10%, following notable progress in<a href="https://www.benzinga.com/news/global/25/05/45337811/trump-announces-total-reset-as-us-china-trade-talks-aim-to-end-tariff-war"> trade discussions</a> held in Geneva over the weekend, as indicated by both the White House and Chinese officials. 
The U.S. will keep its 20% tariffs on Chinese imports related to fentanyl, resulting in a total tariff rate on China of 30%. Treasury Secretary Scott Bessent commented, &#8220;We had very productive talks and I believe that the venue, here in Lake Geneva, added great equanimity to what was a very positive process."
According <a href="https://www.scmp.com/economy/global-economy/article/3309975/china-us-reduce-majority-tariffs-after-first-round-trade-talks?module=top_story&amp;pgtype=homepage">to</a> the South China Morning Post, the joint U.S.-China statement also revealed that Beijing has agreed to lift or suspend all non-tariff countermeasures in place since April 2, which include export restrictions on critical minerals and sanctions on certain U.S. companies. 
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Monday. The SPY was up 3.04% to $581.50, while the QQQ advanced 3.90% to $507.02, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Friday, the SPY was down 0.13% to $564.34, while the QQQ declined 0.066% to $487.97
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45344120/cathie-wood-says-ai-innovation-in-healthcare-will-be-more-profound-than-autonomous-taxi-ne">Cathie Wood Says AI Innovation In Healthcare Will Be More &#8216;Profound&#8217; Than Autonomous Taxi Networks, Humanoid Robots</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

News

Regulations

Broad U.S. Equity ETFs

Futures

Economics

Markets

Analyst Ratings

ETFs

General

US-China Tariff Truce Will Alleviate 'Worst Fears,' But Prevent Falling Yields, Keeping 'Economy Under Pressure,' Says Craig Shapiro

Bill Gates, co-founder of Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), has criticized Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk's recent push for $2 trillion in U.S. government budget cuts, focusing on the dismantling of the U.S. Agency for International Development. 
What Happened: Gates said, in an interview <a href="https://edition.cnn.com/2025/05/09/tech/bill-gates-elon-musk-usaid-cuts-criticism">with</a> CNN, that Musk's aggressive reductions, executed through the Department of Government Efficiency (DOGE) under President Donald Trump&#8216;s administration, could result in millions of deaths worldwide due to the abrupt halt of foreign assistance and health programs.
Gates argued that while efficiency and the use of artificial intelligence in government are laudable goals, Musk's approach has led to slashing critical aid to vulnerable populations. 
"If you show up and say, in two months, you can cut $2 trillion out of a $7 trillion budget, you're not going to succeed," Gates said. "So you go for the softest things and things that are overseas, that you can mischaracterize… people that he hasn't spent any time with." 
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45342343/us-stock-futures-rise-as-us-china-agree-to-90-day-tariff-pause-wider-earnings-growth-should-drive-more-balanced-market-performance-says-expert">US Stock Futures Rise As US, China Agree To 90-Day Tariff Pause: &#8216;Wider Earnings Growth Should Drive More Balanced Market Performance,&#8217; Says Expert</a>
Why It Matters: Gates specifically criticized Musk's false claim that the <a href="https://www.benzinga.com/25/05/45311187/the-picture-of-the-worlds-richest-man-killing-the-worlds-poorest-children-is-not-a-pretty-one-says-bill-gates-slamming-elon-musk-over-abrupt-usaid-cuts">U.S. spent $50 billion on condoms for Gaza</a>, which Musk later retracted, and condemned Musk's negative portrayal of USAID workers, calling them "heroes" and vital to America's global reputation.
The cuts have already disrupted contracts and payments to nonprofits, with aid organizations warning of deadly consequences. U.S. District Judge Theodore Chuang recently blocked further cuts and ordered DOGE to restore some USAID systems, though most contracts remain terminated.
Gates, who recently pledged to give away nearly all his wealth through the Gates Foundation, emphasized that private philanthropy cannot replace the <a href="https://www.benzinga.com/25/05/45311187/the-picture-of-the-worlds-richest-man-killing-the-worlds-poorest-children-is-not-a-pretty-one-says-bill-gates-slamming-elon-musk-over-abrupt-usaid-cuts">scale of government funding for global health</a>. 
"If it was a modest cut and a challenge to be more efficient… I'm fine with that. But 80%, that's going to be millions of deaths and it's a mistake," Gates said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45345409/trumps-big-beautiful-bill-banks-on-huge-medicaid-cuts-as-its-cost-saving-centerpiece-see-who-risks-losing-coverage-under-the-gop-proposal">Trump&#8217;s &#8216;Big, Beautiful Bill&#8217; Banks On Huge Medicaid Cuts As Its &#8216;Cost-Saving Centerpiece&#8217; — See Who Risks Losing Coverage Under The GOP Proposal</a></li>
</ul>
Image Via Shutterstock

MSFT

TSLA

Bill Gates Says Elon Musk's DOGE 'Not Going To Succeed' With $2 Trillion Budget Cut Ambition: 'If You Show Up And Say…'

<a href="https://pr.report/aa4s">Gladstone Commercial Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) ("Gladstone Commercial") is pleased to announce the acquisition of a newly constructed 303,991 square-foot, Class A, fully temperature controlled facility located in Germantown, Wisconsin. This state-of-the-art property was purchased for $62,700,000, providing a weighted average GAAP capitalization rate of 8.74%. The facility includes specialized freezer and cooler storage and was built to support high-capacity pet food production and distribution.
The facility is 100% leased to G&amp;H Pets, LLC through September 2044. The tenant is the in-house manufacturing platform for California Pet Partners, producing premium freeze-dried raw pet food for dogs and cats currently sold under several brands.

GOOD

Gladstone Commercial Acquires $62.7M Class A Temperature-Controlled Facility In Germantown, WI, Fully Leased Through September 2044

WVV Founder Jim Bernau Continues as Chairman and President, Marking Strategic Leadership Succession
SALEM HILLS, Ore., May 12, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4424376-1&amp;h=3969711784&amp;u=https%3A%2F%2Fwww.wvv.com%2F&amp;a=Willamette+Valley+Vineyards">Willamette Valley Vineyards</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>, WVVIP))), one of Oregon's most respected estate wineries, announced today that Mike Osborn, founder of Wine.com, has been named Chief Executive Officer, effective immediately. The appointment follows founder Jim Bernau's January 2025 announcement that he would be stepping back from the CEO role while continuing to serve as President and Chairperson as part of a long-term succession plan.

Management

WVVI

Willamette Valley Vineyards Appoints Mike Osborn As CEO, Effective Immediately

Future Fund LLC's managing director, Gary Black, has shared his thoughts on Pony AI's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) stock as the Chinese AV company gears up for the quarterly results slated to be released next Tuesday.
What Happened: "$PONY AI ($17/share, Nasdaq ADR) is a good way to play future advances in global autonomy, although the stock is clearly overbought." Black said in a post on the social media platform X on Monday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24PONY&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PONY</a> AI ($17/share, Nasdaq ADR) is a good way to play future advances in global autonomy, although the stock is clearly overbought. Until last month, PONY wasn&#39;t doing much for its shareholders (PONY came public in Nov 2024 at $13). A recently announced partnership with Uber,… <a href="https://t.co/M00zIJfIqw">pic.twitter.com/M00zIJfIqw</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1921872478877401242?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He highlighted how the <a href="https://www.benzinga.com/25/05/45225030/robotaxis-take-the-wheel-pony-ai-and-uber-team-up-for-international-rollout">company&#8217;s recent partnership </a>with Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) "has shifted sentiment significantly with $PONY +328% in the past 30 days." Black also cited favorable government regulations in China for the growth.
"PONY has already achieved Level 4 driverless operation in all weather conditions, 24 hours a day." He said. He also mentioned the company's 270-robotaxi-strong fleet, which spans major Chinese cities like Beijing, Guangzhou, Shanghai and Shenzhen, with a planned expansion to 1,000 robotaxis by the end of 2025.
Why It Matters: Ahead of the company's planned Q1 earnings report on May 20, Pony AI has been making moves in the AV sector. The company had announced it would <a href="https://www.benzinga.com/media/25/04/45013465/pony-ai-and-tencent-partner-on-l4-robotaxis-expand-chinas-self-driving-future">partner with Tencent</a> for Level 4 Robotaxis.
Separately, Pony AI also shared that Hesai Group Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) LiDAR tech will power the company's latest<a href="https://www.benzinga.com/25/04/44993180/pony-ai-shares-surge-after-hesai-lidar-partnership-announcement-whats-going-on"> fleet of robotaxis</a>. Hesai had announced its latest LiDAR tech, which would enable Level 3 autonomous driving and feature double the detection distance of its current best-selling model, the AT128.
Price Action: PONY gained 8.20% in Pre-market trading, currently trading for $19.40, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/mid-cap/25/05/45337711/pony-ai-lyft-and-sunrun-are-among-top-9-mid-cap-gainers-last-week-may-5-may-9-are-the-others-in-your-portfolio">Pony AI, Lyft And Sunrun Are Among Top 9 Mid-Cap Gainers Last Week (May 5-May 9): Are The Others In Your Portfolio?</a></li>
</ul>
Photo: Tada Images / Shutterstock

Tech

HSAI

PONY

UBER

Gary Black Weighs In On Pony AI's Growth Ahead Of Earnings Report: 'A Recently Announced Partnership With Uber…'

Maxim Group initiates coverage on Primis Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) with a Buy rating and announces Price Target of $1.

Price Target

Initiation

FRST

Maxim Group Initiates Coverage On Primis Finl with Buy Rating, Announces Price Target of $1

Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types
Rehovot, Israel--(Newsfile Corp. - May 12, 2025) - <a href="https://api.newsfilecorp.com/redirect/YY0qrcbk5p">BioHarvest Sciences Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2 - providing further validation of the versatility of the Company's Botanical Synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing.
Stage 1 of the contract, launched in early 2024, focused on sourcing the required plants to develop a compound used to produce an approved drug product. Completion of Stage 1 indicates that the BioHarvest research team successfully isolated the cells of the target plant and mirrored, magnified and multiplied those cells in petri dishes using the Company's proprietary Botanical Synthesis platform.
Stage 2 involves the delivery of a sufficient amount of biomass to be tested for suitability and involves the development of optimal growing conditions in liquid media. Upon successful completion, the company would transfer to small and medium-scale production and ultimately enter production of commercial volumes of the target compound.

BHST

BioHarvest Completes Stage 1 Development For CDMO Contract With Nasdaq-Listed Pharma Company; Progress Validates Botanical Synthesis Platform for Variety Of Molecule Types

WIIM

FRGT

Freight Technologies shares are trading higher after the company announced it will purchase an additional $1 million of official Trump tokens.

- Bitcoin HODL 148.7 BTC as of April 30, 2025 valued at $14.1 million or $2.75 per share1
TAMPA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) ("LM Funding" or the "Company"), a Bitcoin mining and technology-based specialty finance company, today announced its preliminary, unaudited Bitcoin mining and operational update for the month ended April 30, 2025.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Metric</td>
<td colspan="1">Feb 2025</td>
<td colspan="1">Mar 2025</td>
<td colspan="1">Apr 2025</td>
</tr>
<tr>
<td>- Bitcoin2</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>- Mined, net</td>
<td>7.6</td>
<td>8.7</td>
<td>6.6</td>
</tr>
<tr>
<td>- Sold</td>
<td>-</td>
<td>(14.2)</td>
<td>(18.0)</td>
</tr>
<tr>
<td>- Purchased</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>- Service Fee</td>
<td>(0.0)</td>
<td>(0.1)</td>
<td>(0.1)</td>
</tr>
<tr>
<td>- Bitcoin HODL</td>
<td>165.8</td>
<td>160.2</td>
<td>148.7</td>
</tr>
<tr>
<td>- Machines2</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>- Operational</td>
<td>5,121</td>
<td>5,121</td>
<td>5,121</td>
</tr>
<tr>
<td>- Storage</td>
<td>719</td>
<td>496</td>
<td>496</td>
</tr>
<tr>
<td>- Total Machines</td>
<td>5,840</td>
<td>5,617</td>
<td>5,617</td>
</tr>
<tr>
<td>- Hashrate (EH/s2)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>- Oklahoma</td>
<td>0.43</td>
<td>0.43</td>
<td>0.43</td>
</tr>
<tr>
<td>- Hosted</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
</tr>
<tr>
<td>- Energized</td>
<td>0.56</td>
<td>0.56</td>
<td>0.56</td>
</tr>
<tr>
<td>- Storage</td>
<td>0.07</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>- Total</td>
<td>0.63</td>
<td>0.61</td>
<td>0.61</td>
</tr>
</tbody>
</table>
</figure>
________________________ &nbsp;

LMFA

LM Funding America Bitcoin HODL 148.7 BTC As Of April 30, 2025; Mined 6.6 In April 2025

BYON

Beyond, Inc. Closes $5.2M Expansion Of Existing Credit Facility With Kirkland's, Inc

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hyliion.com%2F&amp;esheet=54252797&amp;newsitemid=20250512429236&amp;lan=en-US&amp;anchor=Hyliion+Holdings+Corp.&amp;index=1&amp;md5=be10a9994924b35124f0089d8032c302">Hyliion Holdings Corp.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) ("Hyliion"), a developer of sustainable electricity-producing technology, today announced it has signed a non-binding Letter of Intent (LOI) for collaboration with Mesa Natural Gas Solutions ("Mesa"), a leading manufacturer and provider of natural gas generators and microgrids.
The LOI outlines a phased demonstration plan for the KARNO&#x2122; Power Module across oil and gas and industrial applications. The LOI includes the purchase of one 200 kW KARNO Power Module and an option to acquire additional Power Modules in 200 kW and 2 MW configurations totaling 2.4 MW in capacity upon completion of successful performance validation. The demonstration will begin with a 200 kW Power Module deployed at a commercial site for stationary power generation using natural gas, followed by deployment at an oil and gas site using wellhead or flare gas.

HYLN

Hyliion Signs LOI With Mesa Natural Gas Solutions To Deploy 200 KW KARNO Power Module

OSIS

OSI Systems' Optoelectronics And Manufacturing Division Secures About $7M Order To Supply Medical Technology Components

-Company issues additional $1 million of convertible notes from existing $20 million facility- -Continues advocacy for fair and free trade across the US-Mexico border-
HOUSTON, May 12, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=q6Fm6yxiygnnhGZr4hl4FfoYsQdj9h5CEHJ9G7GM6faeWiyLLy_uImRMAGiLT6Oc5bmIFh_z_ybv43n-fD7PiaxJdDex6uhMmMzPpBX_0Fg=">Freight Technologies, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>, "Fr8Tech" or the "Company"))), a logistics management innovation company, offering a diverse portfolio of technology-driven solutions, today announced that it has issued two additional convertible notes for $1 million for purchasing <a href="https://www.globenewswire.com/Tracker?data=wZUaU5EP7j4esgDlzURL2ELzSAMWaiNI-0WHvjH7fQV2u6hGeZlxs-hufiUCqXwLm2bYiAD3IDvAqGfLZ7ug8xkvFCekXcRq-iIHxz__89kMtj3k_1J-IHz9iRqhz_RBxvYW7NAOKqqRylJVtwGw-w==">Official Trump ("TRUMP")</a> tokens. This transaction increases Fr8Tech's purchases of TRUMP to $2 million.

$TRUMP

Freight Technologies To Purchase Additional $1M Of Official Trump Tokens, Increasing Fr8Tech's Purchases Of TRUMP To $2M

Hertz Global Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/HTZ/earnings">closing bell on Monday, May 12.</a>
Analysts expect the Estero, Florida-based company to report quarterly losses at 98 cents per share, versus year-ago losses of $1.28 per share in the year-ago period. Hertz Global projects to report quarterly revenue at $2.01 billion, compared to $2.08 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Pershing Square revealed in a regulatory filing last month that the firm purchased 12.71 million shares of Hertz as of Dec. 31, representing a stake of approximately 4.1%.
Hertz Global shares gained 7.7% to close at $6.72 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> &lt;/em>&lt;/a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/htx/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Morgan Stanley analyst Adam Jonas maintained an Equal-Weight rating and cut the price target from $8 to $7 on Aug. 6, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Susquehanna analyst Christopher Stathoulopoulos maintained a Neutral rating and slashed the price target from $5 to $4 on Aug. 6, 2024. This analyst has an accuracy rate of 76%.</li>
<li>Oppenheimer analyst Ian Zaffino maintained a Perform rating on July 5, 2024. This analyst has an accuracy rate of 61%.</li>
</ul>
Considering buying HTZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12040945/image-115-1024x603.png" alt="" class="wp-image-911460" style="width:584px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12040945/image-115-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12040945/image-115-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12040945/image-115-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12040945/image-115.png 1148w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45315727/top-3-industrials-stocks-that-may-collapse-in-may">Top 3 Industrials Stocks That May Collapse In May</a> </li>
</ul>
Photo via Shutterstock

Earnings

Trading Ideas

Top Wall Street Forecasters Revamp Hertz Global Expectations Ahead Of Q1 Earnings

MKTX

MarketAxess Completes Acquisition Of Majority Stake In RFQ-hub Holdings LLC

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 700 points on Monday.
Shares of Orla Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#NYSE">ORLA</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ORLA/earnings">weak quarterly sales</a>.
Orla Mining posted adjusted earnings of 12 cents per share, beating market estimates of 10 cents per share. The company's quarterly sales came in at $140.67 million missing expectations of $163.19 million.
Orla Mining shares dipped 9.5% to $10.05 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares dipped 22.7% to $5.15 in pre-market trading. ReShape Lifesciences filed for mixed shelf offering of up to $50 million.</li>
<li>Global IBO Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) declined 20.1% to $5.58 in pre-market trading after jumping 102% on Friday.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) fell 10.2% to $14.17 in pre-market trading.</li>
<li>AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) fell 10% to $40.30 in pre-market trading. AngloGold Ashanti shares gained 7% on Friday after the company reported better-than-expected first-quarter financial results.</li>
<li>Seabridge Gold Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SA#NYSE">SA</a>) fell 9.4% to $11.38 in pre-market trading.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) shares declined 9.2% to $20.45 in pre-market trading.</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) dipped 8.7% to $6.40 in pre-market trading.</li>
<li>Coeur Mining, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>) fell 6.9% to $7.30 in pre-market trading after gaining 12% on Friday.</li>
<li>Seabridge Gold Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SA#NYSE">SA</a>) fell 6.6% to $11.79 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45315727/top-3-industrials-stocks-that-may-collapse-in-may">Top 3 Industrials Stocks That May Collapse In May</a></li>
</ul>

Pre-Market Outlook

Movers

GIBO

ORLA

RSLS

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019
Company nears start of Registrational Phase 3 study targeted at an addressable market of $7.3Bn
Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the European Commission (EC) has granted Orphan Drug Designation for eRapa in familial adenomatous polyposis (FAP), a largely inherited precancerous disease of the colon for which there is currently no pharmaceutical intervention.

BDRX

Biodexa Pharma Secures EC Orphan Drug Designation For eRapa In FAP Treatment

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Energy Recovery Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERII#NASDAQ">ERII</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Energy Recovery reported worse-than-expected first-quarter financial results. The company's stock fell around 28% over the past five days and has a 52-week low of $10.86.</li>
<li>RSI Value: 20.2</li>
<li>ERII Price Action: Shares of Energy Recovery fell 7.2% to close at $11.37 on Friday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/ERII"><img loading="lazy" decoding="async" width="502" height="168" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082731/image-117.png" alt="" class="wp-image-911820" style="width:320px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082731/image-117.png 502w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082731/image-117-300x100.png 300w" sizes="(max-width: 502px) 100vw, 502px" /></a></figure>
<h3 class="wp-block-heading">Insperity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>)&nbsp;</h3>
<ul class="wp-block-list">
<li>On April 29, Insperity reported worse-than-expected first-quarter financial results, cut its FY25 adjusted EPS guidance, and issued second-quarter adjusted EPS guidance below estimates. &#8220;Our first quarter financial results, reflecting macro-economic turbulence and healthcare cost volatility, are in stark contrast with the solid execution of our game plan for building the foundation for future growth acceleration,&#8221; said Paul J. Sarvadi, Insperity chairman and chief executive officer. The company's stock fell around 23% over the past month and<a href="https://www.benzinga.com/quote/NSP"> has a 52-week low</a> of $61.54.</li>
<li>RSI Value: 29.8</li>
<li>NSP Price Action: Shares of Insperity fell 0.7% to close at $65.92 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0512">NSP stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0512"><img loading="lazy" decoding="async" width="927" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082834/image-118.png" alt="" class="wp-image-911822" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082834/image-118.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082834/image-118-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082834/image-118-768x693.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">Mistras Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Mistras Group reported worse-than-expected first-quarter financial results. Natalia Shuman, President and Chief Executive Officer said, &#8220;Despite the larger than anticipated year-over-year decline in revenue driven by overall market uncertainty, we were nevertheless able to rapidly calibrate costs and expenses down during the first quarter to our revenue level, in order to preserve our operational metrics. With a continued focus on cost and expense management, including a reduction in our administrative support functional costs, and coupled with anticipated revenue growth across all primary industries, we are confident these drivers will provide an improvement in key profitability measures over the remainder of the year.&#8221; The company's stock fell around 16% over the past five days and has a 52-week<a href="https://www.benzinga.com/quote/MG"> low of $7.06</a>.</li>
<li>RSI Value: 28.9</li>
<li>MG Price Action: Shares of Mistras gained 0.4% to close at $7.82 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0512">MG shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0512"><img loading="lazy" decoding="async" width="881" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082923/image-119.png" alt="" class="wp-image-911823" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082923/image-119.png 881w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082923/image-119-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12082923/image-119-768x730.png 768w" sizes="(max-width: 881px) 100vw, 881px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

ERII

Top 3 Industrials Stocks That May Explode This Month

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a genomically defined patient population of non-small <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
The biomarker-focused Phase 1b/2 trial is designed to target high-risk NSCLC subtypes by evaluating LP-184 in combination with Bristol-Myers&nbsp;Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) immune checkpoint inhibitors, Opdivo (nivolumab) and Yervoy (ipilimumab) in patients with advanced NSCLC harboring KEAP1 and/or STK11 mutations and low PD-L1 expression.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45192281/exclusive-lantern-advances-breast-cancer-drug-candidate-with-fda-clearance-for-early-stage-trial" rel="noreferrer noopener">EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial</a>
The study is designed to assess safety, preliminary efficacy, and biomarker correlations, potentially paving a path toward accelerated development.
Lantern Pharma expects to prepare an application for a Fast Track or Accelerated Approval Designation for this patient population based on data from the planned trial and ongoing analysis from existing models.
The company said the median overall survival for newly diagnosed, advanced NSCLC with KEAP1 and/or STK11 mutations treated with checkpoint inhibitors and chemotherapy is estimated to be 15 months, and this population presents an annual market opportunity of over $2 billion.
In December 2024, the FDA granted Fast Track Designation for LP-184 for Triple-Negative Breast Cancer (TNBC). This marked the second Fast Track Designation received for LP-184 in 2024, following its designation <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42287903/lantern-pharmas-investigational-drug-candidate-lp-184-receives-second-fast-track-designation-from-" rel="noreferrer noopener">for Glioblastoma in October</a>.
LP-184 has demonstrated significant preclinical efficacy in TNBC models, including those resistant to PARP inhibitors, and recent data shows promising synergy with checkpoint inhibitors in TNBC.
In November 2024, Lantern Pharma and its wholly-owned subsidiary Starlight Therapeutics announced the presentation of new preclinical data and Phase 1b trial design for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42189336/lantern-pharma-starlight-therapeutics-present-lp-184-star-001-phase-1b-trial-design-and-preclinica" rel="noreferrer noopener">LP-184 in glioblastoma</a>.
Following the determination of the Maximum Tolerated Dose and/or Recommended Phase 2 Dose from the ongoing Phase 1a study, Starlight Therapeutics plans to initiate a Phase 1b trial evaluating LP-184/STAR-001 in two cohorts of recurrent GBM patients: one arm anticipates administration of STAR-001 as monotherapy and the other arm anticipates administration of STAR-001 in combination with spironolactone (200 mg daily).
The trial will assess safety, pharmacokinetics, and objective response using RANO 2.0 criteria. Additionally, the study will evaluate biomarkers, including PTGR1 expression, ERCC3 levels, and DNA damage markers, to help identify patients most likely to respond to treatment.
Price Action: LTRN stock traded lower by 3.02% to $3.86 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45336122/trump-eyeing-nuclear-deal-with-saudi-arabia-china-and-russia-watch-closely" target="_blank" rel="noreferrer noopener">Trump Eyeing Nuclear Deal With Saudi Arabia? China and Russia Watch Closely</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

LTRN

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients

Ramit Sethi has been helping people improve their finances for more than a decade. His book "I Will Teach You To Be Rich" has thousands of Amazon reviews and continues to resonate with many people on their financial journeys.
He recently gave a <a href="https://www.youtube.com/watch?v=GNpMKHnswKs">detailed plan on how to get out of debt</a> and touched upon two popular strategies: the debt snowball method and the debt avalanche method.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
The debt snowball method involves paying off your smallest balances first to build up small wins, while the debt avalanche method prioritizes your balances with the highest interest rates. While Sethi says you should focus on the strategy that's right for you, he identifies the clear winner.
"The avalanche method is mathematically the best choice."
Sethi breaks down why the debt avalanche method is better and when the snowball method makes sense.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
<h2 class="wp-block-heading">Why The Debt Avalanche Method Is Better Than The Debt Snowball Method</h2>
The debt avalanche method can get you out of debt sooner and result in lower interest payments. By prioritizing high-interest debt first, you end up paying less interest as you get out of debt.
A good example is if a borrower had these two debts:
<ul class="wp-block-list">
<li>$1,000 at 5% APR</li>
<li>$10,000 at 20% APR</li>
</ul>
People who follow the debt avalanche method will work harder on the $10,000 balance and only make minimum payments on the $1,000 balance. Making more payments toward the $10,000 balance means less of your money is subject to 20% APR.&nbsp;
On the other hand, the debt snowball method says that you should pay off the entire $1,000 and only make minimum payments on the $10,000 balance. Less of your money will be subject to 5% APR, but you still have 20% APR on your other balance.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Why Some People Should Still Follow The Debt Snowball Method</h2>
Sethi still believes the debt snowball method is valuable because it can give you a small win. For instance, seeing both balances can be frustrating, but eliminating the $1,000 balance can give you some extra motivation.
The debt snowball method is not the most practical strategy, but it can build momentum. Sethi doesn't care which strategy you use as long as you pick one and commit to it. You can change course and prioritize the debt avalanche method if you want to get rid of high APR debt, but it's important to stay focused on paying off debt.
Tracking your debt can help you decide which path is right for you. Some people may have to use the debt snowball method first to get motivated and build momentum. However, if you are already motivated to pay off debt, you will save money if you use the debt avalanche method.
Read Next:
<ul class="wp-block-list">
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Ramit Sethi Breaks Down Debt Snowball Vs. Debt Avalanche Method: 'The Avalanche Method Is Mathematically The Best Choice'

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEUE, ESSA, LTRPA on Behalf of Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into NeueHealth Inc. ("NEUE").

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, AZPN, HEES, NEUE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBRDA, AMPS, NEUE on Behalf of Shareholders

NeueHealth to Host Fourth Quarter 2024 Earnings Conference Call on March 20, 2025

NeueHealth Reports Fourth Quarter and Full Year 2024 Results

NEUEHEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeueHealth, Inc. - NEUE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEUE, BRKL, JWN on Behalf of Shareholders

Comments

NeueHealth

ニュース

最新ニュース NeueHealth (NYSE:NEUE) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル